EGLN1

Across TCGA pan-cancer cohorts, EGLN1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EGLN1 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EGLN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EGLN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where EGLN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.264	0.886	.002	31	view →
LUAD	DFS	Tertile	All	0.396	0.797	.002	16	view →
UCEC	OS	Median	III,IV	1.000	0.507	.022	16	view →
CCRCC	DFS	Median	All	0.638	0.843	.004	15	view →
LSCC	DFS	Tertile	II,III,IV	0.307	0.825	.026	2	view →
PDAC	DFS	Tertile	III,IV	0.470	0.974	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EGLN1–HNSC (DFS)

Open the HNSC breakdown →